Goodrx Holdings, Inc. (GDRX) — SEC Filings
Goodrx Holdings, Inc. (GDRX) — 44 SEC filings. Latest: 8-K (May 6, 2026). Includes 20 8-K, 7 SC 13G/A, 6 10-Q.
View Goodrx Holdings, Inc. on SEC EDGAR
Overview
Goodrx Holdings, Inc. (GDRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: GoodRx Holdings, Inc. (GDRX) reported a mixed financial performance for the three and nine months ended September 30, 2025. For the three months, revenue increased slightly to $196.028 million from $195.251 million in the prior year, a 0.4% rise. However, net income significantly decreased to $1.119
Sentiment Summary
Across 44 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 40 neutral, 1 mixed. The dominant filing sentiment for Goodrx Holdings, Inc. is neutral.
Filing Type Overview
Goodrx Holdings, Inc. (GDRX) has filed 1 4, 20 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 7 SC 13G/A, 3 SC 13D/A, 3 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (44)
Risk Profile
Risk Assessment: Of GDRX's 28 recent filings, 1 were flagged as high-risk, 20 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $196.028M |
| Net Income | $1.119M |
| EPS | N/A |
| Debt-to-Equity | 0.79 |
| Cash Position | $273.529M |
| Operating Margin | 7.5% |
| Total Assets | $1.326B |
| Total Debt | $489.114M |
Key Executives
- Wagner
- Hirsch
- Bezdek
- Amy Schioldager
- David M. Snow
- Douglas Hirsch
- Valerie Lorenz
- Carolina A. Picazo
- Steven A. Schaffer
- David M. Schottenstein
- Sarah A. Schweppe
- Steven R. Wilson
- Laura L. Y. Wu
- Jerome Huguet
- Bansi Nagji
Industry Context
The U.S. healthcare and pharmaceutical landscape is characterized by increasing scrutiny on drug pricing and evolving consumer access models. Companies like GoodRx operate in a dynamic environment influenced by PBMs, retail pharmacies, and government policy. The rise of digital health platforms and direct-to-consumer initiatives are reshaping how patients find and afford medications.
Top Tags
executive-compensation (5) · corporate-governance (4) · 10-Q (4) · legal-proceedings (3) · financials (3) · management-change (3) · board-changes (3) · ownership-change (3) · sec-filing (3) · Healthcare Technology (2)
Executive Compensation
From the most recent DEF 14A filing (Apr 25, 2024):
- Wagner — Member
- Hirsch — Member
- Bezdek — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue (Q3 2025) | $196.028M | Increased from $195.251M in Q3 2024 |
| Net Income (Q3 2025) | $1.119M | Decreased 71.8% from $3.965M in Q3 2024 |
| Net Income (YTD Q3 2025) | $25.014M | Increased 159.2% from $9.650M in YTD Q3 2024 |
| Class A common stock repurchases (YTD Q3 2025) | $206.942M | Significant cash outflow for share buybacks |
| Cash and cash equivalents (Sept 30, 2025) | $273.529M | Decreased from $448.346M at Dec 31, 2024 |
| Stock-based compensation expense (YTD Q3 2025) | $58.707M | Decreased from $78.067M in YTD Q3 2024 |
| Depreciation and amortization (YTD Q3 2025) | $62.072M | Increased from $50.442M in YTD Q3 2024 |
| Q2 2025 Revenue | $200.5M | Increased 11.4% from $180.0M in Q2 2024, indicating strong top-line growth. |
| Q2 2025 Net Income | $15.0M | Swung from a $5.0M net loss in Q2 2024, marking a significant return to profitability. |
| Q2 2025 Selling & Marketing Expense | $60.0M | Decreased from $75.0M in Q2 2024, showing effective cost management. |
| YTD 2025 Revenue | $390.0M | Increased from $350.0M in YTD 2024, demonstrating sustained growth over six months. |
| Q2 Revenue Growth | 11.4% | Percentage increase in revenue from Q2 2024 to Q2 2025, highlighting business expansion. |
| Share Repurchase Authorization | $100M | Maximum amount the company can spend on buying back its own stock. |
| Fiscal Year | 2024 | Primary year for financial data reported |
| SEC File Number | 001-39549 | Identifies the company's filing with the SEC. |
Forward-Looking Statements
- {"claim":"GoodRx Holdings, Inc. may experience increased investor confidence due to Rubric Capital Management LP's significant stake.","entity":"GoodRx Holdings, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Goodrx Holdings, Inc. (GDRX)?
Goodrx Holdings, Inc. has 44 recent SEC filings from Jan 2024 to May 2026, including 20 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GDRX filings?
Across 44 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 40 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Goodrx Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Goodrx Holdings, Inc. (GDRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Goodrx Holdings, Inc.?
Key financial highlights from Goodrx Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GDRX?
The investment thesis for GDRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Goodrx Holdings, Inc.?
Key executives identified across Goodrx Holdings, Inc.'s filings include Wagner, Hirsch, Bezdek, Amy Schioldager, David M. Snow and 11 others.
What are the main risk factors for Goodrx Holdings, Inc. stock?
Of GDRX's 28 assessed filings, 1 were flagged high-risk, 20 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Goodrx Holdings, Inc.?
Recent forward-looking statements from Goodrx Holdings, Inc. include guidance on {"claim":"GoodRx Holdings, Inc. may experience increased investor confidence due to Rubric Capital Management LP's signi.